What to watch for 1

Following the boehringer ingelheim, Craig dean after metformin, astrazeneca Glenn dean sand metformin zyban import applications also review is completed, and metformin, Craig dean, sandy Craig dean metformin zyban also declare the three fixed dose, speculated that might end up also will only two batch of fixed specifications. Two kinds of oral compound preparations for hypoglycemia have entered China successively, and it depends on the market situation in the later stage.

What to watch for 2

SH229 tablets, a class 1 new drug of Nanjing Shenghe, were approved for clinical application. This product was undertaken in December 2016. In the thirteenth batch of "Publicity of drug registration Application to be included in the Priority Review Procedure", it was a direct antiviral drug for the treatment of hepatitis C.
In addition, since 2017, Nanjing Shenghe has also submitted a class 1 new drug, namely SH526 tablets.

What to watch for 3

Inlebuvir sodium tablets, a class 1 new drug of Guangdong East Sunshine, was approved for clinical use in December 2016. In the 14th batch of "Publicity of drug registration application to be included in the Priority Review Procedure", it was also a direct antiviral drug for the treatment of hepatitis C.
East Sunshine has declared a lot of 1 (1.1) new drugs in recent years. Xiaobian takes you to have a look:

What to watch for 4

Shengshitaike's Class 1 new drug phosphate Shengagliptin tablet was approved clinically. This product was undertaken in October 2016 for the treatment of type 2 diabetes mellitus.
At present, class 1 DPP4 inhibitors in China include reagliptin of Hengrui, Euagliptin tablets of Chengdu Yuandong, Fuagliptin capsules of Chongqing Fuchuang, Eglliptin tablets of Shandong Luye, and eglliptin tablets of Shandong Xuanxu. At present, only ogliptin tablets from Nanjing Changao and Bergerliptin tablets from Jiangsu Hausen have not been found in the CDE registration platform for the category of "liptin" that has received clinical approval. I don't know why. But this week another liptin was approved for clinical use, so let's all do it.

What to watch for 5

ZSP1602 capsule, a class 1 new drug of Guangdong Sentient Beings, was clinically approved in October 2016. It is a class 1 innovative drug for the treatment of small cell lung cancer and other malignant tumors, with specifications of 10mg and 50mg.
ZSP1601 tablet, ZSP1602 capsule and ZSP1603 capsule are the three drugs jointly developed by Guangdong Sentient and wuxi Apptec. Currently, only ZSP1602 capsule has been approved clinically, and we are looking forward to the approval of the other two.

What to watch for 6

The clinical application of rivaroxaban granules was submitted by Bayer Pharmaceuticals (JXHL1700086, registration classification 2.2), which was not marketed at home and abroad.
Rivaroxaban tablets were first imported by Bayer Pharmaceuticals in 2009 for use in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis. From the listing date to 2016, the sales volume of rivaroxaban has been rising all the way, and by 2016, the sales volume of Rivaroxaban in sample hospitals has exceeded 250 million yuan.